Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Study Overview: This study is about how genes might affect the way heart failure patients respond to a medicine called SGLT2 inhibitors, which help with heart failure and were first used for diabetes. The SGLT2 gene is a part of our DNA that helps make this medicine work. Some people have gene changes, or mutations, that might change how well the medicine works for them.
Who Can Join: People with heart failure, who are candidates for SGLT2 treatment and can sign a consent form, may join. However, if you have certain heart surgeries recently, are pregnant, or have other specific health issues, you cannot join.
- Study Length: The study involves multiple visits to the clinic.
- Risks: There are no major risks, but some people might not respond to the treatment as expected.
- Compensation: Check with the study coordinator if there is any compensation for participation.
For more information, talk to your doctor to see if this study is right for you. 😊
Study details
NCT06201000
October 6 University
24 January 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.